南京医药
(600713)
| 流通市值：64.47亿 | | | 总市值：65.58亿 |
| 流通股本：12.87亿 | | | 总股本：13.09亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 27,967,411,701.62 | 14,246,884,352.7 | 53,696,173,895.8 | 40,938,180,822.52 |
| 营业收入 | 27,967,411,701.62 | 14,246,884,352.7 | 53,696,173,895.8 | 40,938,180,822.52 |
| 二、营业总成本 | 27,397,599,436.31 | 13,943,368,597.83 | 52,651,384,912.88 | 40,123,096,334.31 |
| 营业成本 | 26,313,158,514.68 | 13,397,551,742.47 | 50,323,077,943.02 | 38,414,540,220.25 |
| 税金及附加 | 58,521,897.43 | 28,768,607.11 | 116,270,967.76 | 85,321,921.41 |
| 销售费用 | 553,796,458.6 | 291,361,696.08 | 1,148,152,134.81 | 845,968,276.41 |
| 管理费用 | 218,463,530.58 | 98,418,095.61 | 517,660,434.62 | 346,175,353.89 |
| 研发费用 | 18,480,170.5 | 9,115,551.48 | 30,635,024.74 | 30,536,340.65 |
| 财务费用 | 235,178,864.52 | 118,152,905.08 | 515,588,407.93 | 400,554,221.7 |
| 其中:利息费用 | 144,985,507.7 | 69,466,148.85 | 325,820,558.4 | 266,514,175.23 |
| 其中:利息收入 | 7,843,878.68 | 6,069,321.19 | 13,605,914.39 | 10,172,311.34 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 383,768.34 | 353,888.89 | - | - |
| 加:投资收益 | -1,476,139.27 | 178,683.57 | 4,018,269.49 | 3,096,723.62 |
| 资产处置收益 | 8,651,959.87 | 2,921,757.69 | 4,149,625.86 | 4,301,998.51 |
| 资产减值损失(新) | -3,827,050.29 | 2,164,228.26 | -18,267,214.45 | -2,124,236.1 |
| 信用减值损失(新) | -78,540,142.16 | -41,738,533.1 | -41,934,892.82 | -68,814,673.14 |
| 其他收益 | 13,177,443.67 | 7,548,166.51 | 30,649,336.29 | 20,063,924.66 |
| 四、营业利润 | 508,182,105.47 | 274,943,946.69 | 1,023,404,107.29 | 771,608,225.76 |
| 加:营业外收入 | 32,651,681.85 | 7,717,490.51 | 12,410,842.01 | 8,418,950.45 |
| 减:营业外支出 | 13,980,304.14 | 6,325,837.47 | 32,419,560.8 | 17,472,745.23 |
| 五、利润总额 | 526,853,483.18 | 276,335,599.73 | 1,003,395,388.5 | 762,554,430.98 |
| 减:所得税费用 | 147,103,953.74 | 60,752,142.38 | 260,275,394.61 | 198,747,894 |
| 六、净利润 | 379,749,529.44 | 215,583,457.34 | 743,119,993.89 | 563,806,536.98 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 379,749,529.44 | 215,583,457.34 | 743,119,993.89 | 563,806,536.98 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 291,276,712.36 | 177,360,973 | 570,627,552.6 | 441,882,390.22 |
| 少数股东损益 | 88,472,817.08 | 38,222,484.34 | 172,492,441.29 | 121,924,146.76 |
| 扣除非经常损益后的净利润 | 261,657,491.87 | 169,551,146.65 | 575,411,077.04 | 435,532,338.75 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.22 | 0.14 | 0.44 | 0.34 |
| (二)稀释每股收益 | 0.2 | 0.14 | 0.44 | 0.34 |
| 八、其他综合收益 | -1,489,536.52 | -7,229,191.85 | 12,772,851.86 | 28,155,158.32 |
| 归属于母公司股东的其他综合收益 | -1,554,116.86 | -6,878,094.3 | 12,572,743.16 | 27,157,780.85 |
| 九、综合收益总额 | 378,259,992.92 | 208,354,265.49 | 755,892,845.75 | 591,961,695.3 |
| 归属于母公司股东的综合收益总额 | 289,722,595.5 | 170,482,878.7 | 583,200,295.76 | 469,040,171.07 |
| 归属于少数股东的综合收益总额 | 88,537,397.42 | 37,871,386.79 | 172,692,549.99 | 122,921,524.23 |
| 公告日期 | 2025-08-30 | 2025-04-30 | 2025-04-10 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |